Skip to content
Menu

Corgi ONTO 2x Daily ETF ONTX

Full chart Compare
Set alert

Price alert · ONTX

All alert types
4.72 USD -1.66 (-26.06%)

As ofNov 20, 2026, 1:43 PM EST

4.66 Day range 4.75
4.19 52-week range 43.14
YTD
-81.61%
1 year
-81.61%

5D -0.70 (-9.46%)

67ThuFriMonTue6.70
Assets
$693.63K
Expense ratio
0.45%
NAV
6.43
Holdings
1
Asset class
Leveraged/Inverse
Issuer
Corgi Funds
Inception
Jun 24, 2026
YTD return
-81.61%
1-year return
-81.61%
Volume
11.76K
Avg volume
14.96K
Open
4.75
Previous close
6.38
Day's range
4.66 – 4.75
52-week range
4.19 – 43.14
50-day average
0.815224
200-day average
0.783364

About Corgi ONTO 2x Daily ETF

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
onconova.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on ONTX — it syncs with the Stock Master app.